1	COVID-19 outcomes associated with clinical and demographic characteristics in patients
2	hospitalized with severe and critical disease in Peshawar
3	Muhammad Imran ¹ , Azharuddin ¹ , Muhammad Yousaf ² , Sajjad Khan ³ , Abdul Jalil Khan ⁴ , Zafar
4	Iqbal ^{1*} , RahmanUllah Jan ² , Shahid Khan ⁵ Muhammad Salman Khan ⁶
5	¹ MTI, Lady Reading Hospital, Peshawar, Pakistan
6	² COVID-19 Hospital, Nishterabad, Peshawar, Pakistan
7	³ Indiana University (IU) School of Public Health, IU, Bloomington, USA
8	⁴ Khyber Medical University, Peshawar, Pakistan
9	⁵ Health Sector Reforms Unit, Health Secretariat, Peshawar, Pakistan
10	⁶ Northwest General Hospital and Research Center, Peshawar, Pakistan
11	Short title: COVID-19 outcomes associated with clinical and demographic characteristics
12	*Corresponding Author
13	Dr Zafar Iqbal (MBBS, FCPS)
14	Assistant Professor, Pulmonology
15	Lady Reading Hospital, Peshawar
16	25000, Pakistan.
17	E-mail: drzafariqbalpulmo@gmail.com (ZI)
18	

19 Abstract

Background: As a novel disease, understanding the relationship between the clinical and 20 demographic characteristics of coronavirus disease 2019 (COVID-19) patients and their outcome 21 22 is critical. We investigated this relationship in hospitalized patients in a tertiary healthcare setting. 23 Aims/objectives: To study COVID-19 severity and outcomes in relation to clinical and 24 demographic characteristics of in admitted patients 25 Methodology: In this cross-sectional study, medical records for 1087 COVID-19 patients were 26 reviewed to extract symptoms, comorbidities, demographic characteristics, and outcomes data. 27 Statistical analyses included the post-stratification chi-square test, independent sample t-test, 28 29 multivariate logistic regression, and time-to-event analysis. 30 **Results:** The majority of the study participants were >50 years old (67%) and male (59%) and 31 had the following symptoms: fever (96%), cough (95%), shortness of breath (73%), loss of taste (77%), and loss of smell (77%). Regarding worst outcome, multivariate regression analysis 32 showed that these characteristics were statistically significant: shortness of breath (adjusted odds 33 34 ratio [aOR] 31.3; 95% CI, 11.87–82.53; p < 0.001), intensive care unit (ICU) admission (aOR 35 28.3; 95% CI,9.0–89.6; p < 0.001), diabetes mellitus (aOR 5.1; 95% CI;3.2–8.2; p < 0.001), ischemic heart disease (aOR 3.4; 95% CI, 1.6–7; p = 0.001), nausea and vomiting (aOR 3.3; 95% 36 37 CI, 1.7–6.6; p = 0.001), and prolonged hospital stay (aOR 1.04; 95% CI, 1.02–1.08; p = 0.001), while patients with rhinorrhea were significantly protected (aOR 0.3; 95% CI, 0.2–0.5; $p < 10^{-10}$ 38

- 39 0.001). A Kaplan–Meier curve showed that the symptoms of shortness of breath, ICU admission,
- 40 fever, nausea and vomiting, and diarrhea increased the risk of mortality.
- 41 Conclusion: Increasing age, certain comorbidities and symptoms, and direct admission to the
- 42 ICU increased the risk of worse outcomes. Further research is needed to determine risk factors
- that may increase disease severity and devise a proper risk-scoring system to initiate timely
- 44 management.

45

- 46 Keywords: COVID-19, SARS-CoV-2, clinico-demographic characteristics, mortality, outcomes
- 47
- 48

50 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus 51 disease 2019 (COVID-19), a member of the coronavirus family that was responsible for the 2003 52 53 SARS epidemic [1]. The World Health Organization (WHO) declared the outbreak to be a Public Health Emergency of International Concern on January 30, 2020, and declared it to be a global 54 pandemic on March 11, 2020 [2]. The virus has affected almost every country, every nation, and 55 56 all races worldwide. The WHO has reported 269.2 million confirmed cases of COVID-19 and 5.30 million deaths internationally as of December 10, 2021 [3]. Although 8.42 billion vaccine 57 doses were administered worldwide by December 10, only a little more than 64 million doses 58 have been administered in low-income countries [3]. With the emergence of the Omicron 59 variant, the disease is surging again in various parts of the world, thereby posing a challenge to 60 vaccination measures [3]. At the time of this writing, the total number of COVID-19 infections 61 in Pakistan is 1.28 million, with slightly less than 30,000 deaths [4]. Although the vaccination 62 drive was initially slow in Pakistan, its pace is quickening. As of December 8, 2021, 130 million 63 64 vaccine doses have been administered throughout Pakistan, whereas only 54 million people have been fully vaccinated, defined as having either completed the single-dose vaccine or both doses 65 of the two-dose vaccine [4]. 66

The clinical presentation of COVID-19 is variable [5]. It ranges from asymptomatic infection or
mild upper respiratory symptoms in most cases to severe viral pneumonia with respiratory failure
[6]. In most infected individuals, no symptoms or only minimal symptoms appear [7].
Symptomatic patients present with variable symptoms. The most common are fever, cough,
generalized body aches, shortness of breath, anosmia, and loss of taste. The uncommon

symptoms are headache, nausea, and diarrhea [6]. Fever is the most prevalent reported symptom 72 [8]. Continuous fever, shortness of breath, and presence of respiratory and gastrointestinal 73 symptoms make a patient prone to develop severe disease. Moreover, the likelihood of intensive 74 care unit (ICU) admission, mechanical ventilation (invasive and non-invasive), and death is high 75 in such patients. In a study by Rongchen [9] et al., gastrointestinal symptoms were more strongly 76 77 linked with worse outcomes. In Nigeria, Akin Abayomi [10] et al. found that cough, high-grade fever, and shortness of breath were the most common presenting symptoms. Symptom severity 78 79 was the most important predictor of death. Among all other symptoms, shortness of breath had a 80 worse prognostic value in terms of mortality. In contrast, isolated loss of the sense of smell and sense of taste was not linked with the development of critical disease and thus had good 81 prognostic value. 82

Significant risk factors associated with worse outcomes are chronic illness, older age, and
genetic predisposition [11]. In a study by Elizabeth [12] et al., older age was the most significant
risk factor for death, followed by hematologic malignancies, immunosuppressive drugs, organ
transplantation, uncontrolled diabetes mellitus, black race, and obesity. A study from Pakistan by
Ambreen Chaudhry [13] et al. found that the risk factors responsible for worse outcomes, defined
as ICU admission, invasive mechanical ventilation (IMV), and death, were older age and the
presence of comorbidities.

Several studies have reported different mortality rates for patients admitted to different hospital
departments, such as the ICU, high-dependency unit, and general ward. Mortality is highest for
patients receiving IMV, followed by those managed with continuous positive airway
pressure/non-invasive ventilation, high-flow nasal cannula, and oxygen administered via other

- 94 devices such as a simple face mask and nasal prongs [14]. The outcomes are good for patients
- who do not require supplemental oxygen and hospital admission [15].
- 96 The objective of the current study is to understand the demographic and clinical characteristics of
- 97 patients with COVID-19 and the associated severity of illness and outcomes. We sought to
- 98 perform an in-depth analysis of the various factors related to mortality, morbidity, and recovery
- 99 from COVID-19. In Pakistan, data are very limited on the clinical and demographic
- 100 characteristics of patients with COVID-19. Therefore, the results of this study will help us tailor
- 101 our management and preparedness response to the COVID-19 pandemic.
- 102 This article was previously presented as an abstract at the 14th Biennial Chest Conference
- arranged by the Pakistan Chest Society at Karachi, Pakistan, on 4 December, 2021.

104

106 Material and Methods

107	This cross-sectional study was conducted from July 15, 2020, to July 3, 2021 in Peshawar,
108	Khyber Pakhtunkhwa, Pakistan. All patients admitted to the study hospital were included in our
109	study. Patients who were referred to another hospital or left without medical advice were
110	excluded from our study. Informed written consent was obtained from all patients at admission
111	to the hospital. The analysis was performed using SPSS, version 25 (IBM, Armonk, NY, USA)
112	[16]
113	The association of various characteristics with mortality was analyzed. We used the post-
114	stratification chi-square test and independent sample t-test to check the statistical significance of
115	qualitative and quantitative characteristics, respectively. A value of $p \leq 0.05$ was considered
116	statistically significant. To assess the adjusted association, we used multivariate logistic
117	regression, with mortality as a dependent variable. These predictor variables were included in the
118	final multivariate regression model, with a value of $p \leq 0.25$ on the univariate model as the
119	dependent variable. In the final multivariate model, a value of $p \leq 0.05$ was considered
120	significant. Time-to-event analysis was conducted to check for the difference in mortality across
121	various groups.

122 **Results**

- 123 This study assessed a total of 1087 patients, of whom 449 (41%) were female and 731 (67%)
- were older than 50 years (Table 1). Most had a fever (96.4%), cough (95.3%), shortness of
- breath (72.7%), loss of taste (76.6%), and loss of smell (76.5%). Patients presented relatively less
- 126 commonly with headache (28.1%), rhinorrhea (32.8%), nausea and vomiting (12.8%), and
- diarrhea (12.1%). Among comorbid conditions, hypertension (29.7%) and diabetes mellitus
- 128 (24.4%) were more common compared with ischemic heart disease (9%) and end-stage renal
- disease (1.3%). The average length of hospital stay was 8.33 days. The overall mortality rate was
- 130 24.4% (268 patients) and was highest among those admitted directly to the ICU (49 of 56
- patients, 88%) versus those admitted directly to the high-dependency unit (210 of 546 patients,
- 132 38%) and the general ward (9 of 485, 1.8%).

Characteristics	No.	%	
Age			
	Below 50 years	356	33%
	Above 50 years	731	67%
Gender			
	Female	449	41%
	Male	638	59%
Fever			
	No	39	4%
	Yes	1048	96%
Cough			
	No	51	5%
	Yes	1036	95%
Headache			
	No	782	72%
	Yes	305	28%
Shortness of Breath			
	No	297	27%
	Yes	790	73%
Rhinorrhoea			

133 Table 1. Frequency of various characteristics of study participants (n = 1087).

	No	730	67%
	Yes	357	33%
Loss of taste			
	No	254	23%
	Yes	833	77%
Diarrhea			
	No	955	88%
	Yes	132	12%
Nausea and Vomiting			
	No	948	87%
	Yes	139	13%
Loss of Smell			
	No	255	23%
	Yes	831	77%
Diabetes Mellitus			
	No	822	76%
	Yes	265	24%
Hypertension			
	No	764	70%
	Yes	323	30%
Ischemic Heart Disease			
	No	989	91%
	Yes	98	9%
End-Stage Renal Disease			
	No	1073	99%
	Yes	14	1%
Days of Hospitalization			
	mean (SD)	8.33 (7.94)	
Severity Level			
	Moderate	146	13%
	Severe	941	87%
Unit of Admission			
	HDU / Isolation ward	1031	95%
	ICU	56	5%
Mortality			
	Recovered	819	63%
	Died	268	24%

134

135 Simple stratification (Table 2) showed that mortality was significantly higher in patients older

than 50 years (37% vs. 11%) and in those with shortness of breath (41% vs. 2%), diarrhea (60%

- 137 vs. 24%), nausea and vomiting (60% vs. 23%), diabetes mellitus (62% vs. 16%), hypertension
- 138 (53% vs. 18%), ischemic heart disease (74% vs. 24%), high level of disease severity (33% vs.
- 139 0%), and ICU admission (92% vs. 25%). Although mortality was also higher in female patients
- 140 (31% vs. 27%) and in those with fever (29% vs. 16%), and end-stage renal disease (100% vs.
- 141 28%), the association was not statistically significant. Some characteristics showed a statistically
- significant protective effect from mortality, such as rhinorrhea (12% vs. 37%), loss of taste (2%
- vs. 100%), and loss of smell (2% vs. 100%). Length of stay was also significantly higher in
- 144 patients who died compared with those who survived (11.43 vs. 7.63 days).

145

146 Table 2. Association of various characteristics with mortality.

Characteristics		Mortality					
		D	ied	Recovered		*p-value	
		No.	%	No.	%	_	
Age							
	Below 50 years	35	11%	277	89%	< 0.001	
	Above 50 years	233	37%	394	63%		
Gender							
	Female	118	31%	266	69%	0.217	
	Male	150	27%	405	73%		
Fever							
	No	6	16%	31	84%	0.090	
	Yes	262	29%	640	71%		

Cough						
	No	16	32%	34	68%	0.578
	Yes	252	28%	637	72%	
Headache						
	No	197	29%	480	71%	0.543
	Yes	71	27%	191	73%	
Shortness	of Breath					
	No	5	2%	290	98%	< 0.001
	Yes	263	41%	381	59%	
Rhinorrhe	a					
	No	232	37%	394	63%	< 0.001
	Yes	36	12%	277	88%	
Loss of tas	te					
	No	254	100%	0	0%	< 0.001
	Yes	14	2%	671	98%	
Diarrhea						
	No	191	24%	620	76%	< 0.001
	Yes	77	60%	51	40%	
Nausea an	d Vomiting					
	No	186	23%	617	77%	< 0.001
	Yes	82	60%	54	40%	
Loss of Sm	nell					

	No	255	100%	0	0%	< 0.001
	Yes	12	2%	671	98%	
Diabetes	Mellitus					
	No	113	16%	577	84%	< 0.001
	Yes	155	62%	94	38%	
Hyperter	ision					
	No	116	18%	535	82%	< 0.001
	Yes	152	53%	136	47%	
Ischemic	Heart Disease					
	No	201	24%	647	76%	< 0.001
	Yes	67	74%	24	26%	
End-Stag	ge Renal Disease					
	No	264	28%	671	72%	-
	Yes	4	100%	0	0%	
Days of H	Hospitalization					
	mean (SD)	11.43 (10.28)		7.63 (6.64)		< 0.001 a
Severity	Level					
	Moderate	0	0%	136	100%	< 0.001
	Severe	268	33%	535	67%	
Unit of A	dmission at Arrival					
	HDU / isolation	219	25%	667	75%	< 0.001

ICU	49	92%	4	8%	

147 * p-value represents results of chi-square test

148 ^a p-value represents results of independent samples t-test

149

- 150 On multivariate regression (Table 3), several characteristics were statistically significant, as
- follows: shortness of breath (adjusted odds ratio [aOR] 31.3; 95% CI, 11.87–82.53; p < 0.001),
- 152 ICU admission (aOR 28.3; 95% CI, 9.0–89.6; p < 0.001), diabetes mellitus (aOR 5.1; 95% CI,
- 153 3.2–8.2; p < 0.001), ischemic heart disease (aOR 3.4; 95% CI, 1.6–7; p = 0.001), nausea and
- vomiting (aOR 3.3; 95% CI, 1.7-6.6; p = 0.001) and prolonged hospital stay (aOR 1.04; 95% CI,
- 155 1.02-1.08; p = 0.001). These findings that the odds of shortness of breath was 31.3 times, ICU
- admission was 28.3 times, diabetes mellitus was 5.1 times, ischemic heart disease was 3.4 times,
- 157 nausea and vomiting was 3.3 times, and prolonged hospital stay was four times higher in patients
- 158 who died compared with those who survived. Patients with rhinorrhea were significantly
- 159 protected on a multivariate model (aOR 0.3; 95% CI, 0.2-0.5; p < 0.001).

160

161

162 Table 3. Multivariate logistic regression analysis of various characteristics.

Characteristics		aOR ^a 95% CIs		o CIs	p-value	
			Lower	Upper		
Gender						
	Female	Ref				

	Male	0.725	0.483	1.086	0.119
*Fever					
	No	Ref			
	Yes	5.526	1.442	21.174	0.013
*Shortness	of Breath				
	No	Ref			
	Yes	31.302	11.873	82.525	< 0.001
*Rhinorrhe	ea				
	No	Ref			
	Yes	0.302	0.183	0.500	< 0.001
Diarrhea					
	No	Ref			
	Yes	1.262	0.633	2.515	0.509
*Nausea an	d Vomiting				
	No	Ref			
	Yes	3.347	1.688	6.639	0.001
*Diabetes N	Aellitus				
	No	Ref			
	Yes	5.079	3.153	8.179	< 0.001
Hypertensi	on				
	No	Ref			
	Yes	1.546	0.963	2.481	0.071
*Ischemic I	Heart Disease				

	No	Ref			
	Yes	3.369	1.628	6.969	0.001
*Days of Hosp	oitalization	1.048	1.020	1.077	0.001
*Unit of Admi	ission				
	HDU /	Ref			
	Isolation ward				
	ICU	28.330	8.955	89.631	< 0.001

163 * p-value represents results of chi-square test

^a p-value represents results of independent samples t-test

165

166 The survival analysis comprised 1087 patients. Our analysis observed a cumulated total risk time

167 of 9184 days. The Kaplan–Meier survival plots for the sociodemographic and medical factors

that were statistically significant are presented in Figure 1. As can be inferred from the plots,

patients with fever (Fig 1A), shortness of breath (Fig 1B), ischemic heart disease (Fig 1C),

170 nausea and vomiting (Fig 1D), diabetes mellitus (Fig 1E), and ICU admission (Fig 1F) were

171 more likely to die compared with patients who did not have these signs and symptoms.

172 Fig 1 Title: K-M Curves for various characteristics

173 Fig 1 Legend: As shown, patients with fever (A), shortness of breath (B), ischemic heart disease

174 (C), nausea and vomiting (D), diarrhea (E), and ICU admission (F) were more likely to encounter

the worst outcome as compared with patients who did not have these characteristics.

176

177 **Discussion**

The severity of any given disease depends on the population's demographic and clinical 178 characteristics [17]. Therefore, we aimed to study these factors to understand COVID-19 in 179 detail. This study will help us improve the management steps to prevent severe disease 180 outcomes. Clinicians and scientists are performing many kinds of studies to understand this 181 novel disease, which has killed millions of people. Many studies have already been conducted, 182 183 but with several drawbacks, such as a small sample size. Although this current investigation is a single-site study, the hospital is an ideal location to examine the COVID-19 cohort because it 184 185 serves as a referral center for most of the province. This study included 1087 patients with 186 COVID-19 from a single tertiary care institution. Our hospital had an overall mortality rate of 187 24%, which is comparable with that of most nearby tertiary care hospitals. In a multi-center 188 study conducted by Zia Ul Haq [18] et al. in Peshawar, Pakistan, the inpatient mortality rate in a cohort of 179 patients was 29.1%. 189

The findings show that certain clinical and demographic factors may predispose patients to 190 worse outcomes. Severe shortness of breath (OR 31) and admission to the ICU on presentation 191 (OR 28), for example, were the strongest predictors of worse outcomes in our analysis, in favor 192 of mortality. Direct admission to the ICU indicates that the patient's condition is rapidly 193 194 deteriorating or that the patient arrived at the hospital very late and in critical condition. Furthermore, symptoms such as nausea and vomiting (OR 3.9), fever (OR 3.5), and diarrhea, 195 (OR 1.52) predispose one to worse outcomes as well. In contrast, our study found that rhinorrhea 196 indicated a higher likelihood of recovery, which has not been reported previously. In a survey by 197

198	Nausheen Nasir [19] et al. in Karachi, Pakistan, disease severity was associated with age older
199	than 60 years (OR 1.92) and having shortness of breath (OR 4.43). In another study, Darbaz A
200	[20] et al. in the United States found that patients presenting with gastrointestinal symptoms had
201	higher hospitalization rates, ICU admission, and intubation. In contrast, Preethi Ramachandran
202	[21] et al. compared the outcomes in two groups of patients with or without gastrointestinal
203	symptoms and discovered that mortality did not differ between cases and controls (41.9% vs.
204	37.8%; $p = 0.68$). Secondary outcomes, such as length of stay (7.8 vs. 7.9 days; $p = 0.87$) and
205	need for mechanical ventilation (29% vs. 26.9%; $p = 0.82$), also showed no statistically
206	significant differences.
207	Many studies have found that the presence of comorbidities such as diabetes, hypertension,
208	ischemic heart disease, and end-stage renal disease increases the severity of the disease [22, 23].
209	In our research, we came to a similar conclusion. According to the survival analysis in our study,
210	patients with diabetes mellitus, hypertension, and ischemic heart disease had a lower chance of
211	survival when admitted to the hospital with COVID-19 than patients without any of these
212	comorbidities. Due to the small sample size, the findings could not be statistically tested because
213	most patients who developed end-stage renal disease in our study were referred to other hospitals
214	with dialysis services. Other authors have reported similar results. Naila Shoaib [24] et al. in
215	Pakistan discovered a link between the severity of COVID-19 and the number and type of
216	comorbidities. As the number of comorbidities increased, so did the disease severity. Patients
217	who were older, had diabetes, or had high blood pressure were more likely to have a poor
218	outcome.

Our study was conducted at a tertiary care hospital with a large sample size for one hospital. The study sample was diverse because the patients were referred from throughout the province to this tertiary care hospital. We evaluated both demographic and clinical characteristics to perform an in-depth analysis.

The limitations of this study are that we did not include patients from other hospitals for comparative analysis. Furthermore, we did not include the response to various treatments, and lastly, the patient's social characteristics, such as local residence, occupation, and income, were not included in this analysis.

227 Further research is needed to develop a comprehensive scoring system for COVID-19. The

system for scoring should be practical and straightforward to predict the disease severity and the management steps for COVID-19. Both prospective and retrospective analyses from the global

north and the global south are needed to identify the critical factors in managing this disease.

231

232 **Conclusions**

Our findings showed that older age, comorbidities, and direct admission to the ICU increase the risk of worse outcomes. Furthermore, shortness of breath, fever, and gastrointestinal symptoms also increase the risk of worse outcomes. In contrast, patients with isolated upper respiratory symptoms have a lower mortality rate. More research is needed to determine risk factors that increase the risk of disease severity and to devise a proper risk scoring system to initiate timely management.

- 240 Acknowledgments:
- 241 **Ethical Approval**: Ethical approval for the study was taken from Ethics Committee, Office of
- 242 Research Innovation & Commercialization (ORIC), Khyber Medical University, Peshawar,
- 243 bearing number DIR/KMU-EB/DO000667.
- 244 Informed written consent was taken from all the participants.

245 **References:**

- 246 1. Zheng J. SARS-CoV-2: An emerging coronavirus that causes a global threat. Int J Biol
- 247 Sci. 2020;16(10): 1678-1685. doi: <u>10.7150/ijbs.45053</u>.
- 248 2. Detail. Who.int. 2020 [cited Dec 13, 2021]. Available from:
- 249 https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-
- at-the-media-briefing-on-covid-19---11-march-2020.
- 251 3. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J. Coronavirus pandemic
- 252 (COVID-19). Our World Data. 2020 [cited Dec 14, 2021]. Available from:
- 253 https://ourworldindata.org/covid-cases.
- 4. National command operation center: national command operation center. 2021 [cited Dec
- 13, 2021]. Available from: https://ncoc.gov.pk/covid-vaccination-en.php.
- 5. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira
- 257 T, Campos Alcântara R, et al. Clinical manifestations of COVID-19 in the general population:

systematic review. Wien Klin Wochenschr. 2021;133(7-8): 377-382. doi: 10.1007/s00508-02001760-4.

260 6. Vihta KD, Pouwels KB, Peto T, Pritchard E, Eyre DW, House T, et al. Symptoms and

261 SARS-CoV-2 positivity in the general population in the UK. Clin Infect Dis. 2021. doi:

262 <u>10.1093/cid/ciab945</u>.

7. Alene M, Yismaw L, Assemie MA, Ketema DB, Mengist B, Kassie B, et al. Magnitude
of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and
meta-analysis. PLOS ONE. 2021;16(3): e0249090. doi: <u>10.1371/journal.pone.0249090</u>.

- 266 8. Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and
- characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-
- 19): A systematic review and meta-analysis of 17515 patients. PLOS ONE. 2021;16(4):
- e0249788. doi: <u>10.1371/journal.pone.0249788</u>.
- 270 9. Chen R, Yu YL, Li W, Liu Y, Lu JX, Chen F, et al. Gastrointestinal symptoms associated
- with unfavorable prognosis of COVID-19 patients: A retrospective study. Front Med (Lausanne).
- 272 2020;7: 608259. doi: <u>10.3389/fmed.2020.608259</u>.
- 273 10. Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-
- 274 Peñacoba G, et al. Anosmia is associated with lower in-hospital mortality in COVID-19.
- 275 J Neurol Sci. 2020;419: 117163. doi: <u>10.1016/j.jns.2020.117163</u>.
- 11. Liu X, Yue X, Liu F, Wei L, Chu Y, Bao H, et al. Analysis of clinical features and early
- warning signs in patients with severe COVID-19: A retrospective cohort study. PLOS ONE.
- 278 2020;15(6): e0235459. doi: <u>10.1371/journal.pone.0235459</u>.
- 279 12. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
- associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821): 430-
- 281 436. doi: <u>10.1038/s41586-020-2521-4</u>.
- 13. Chaudhry A, Ikram A, Baig MA, Salman M, Ghafoor T, Zakir H, et al. Mortality analysis
- of COVID-19 confirmed cases in Pakistan. medRxiv [preprint]. 2020 Jan 1. doi:
- **284** <u>10.1101/2020.06.07.20121939</u>.
- 285 14. Rahim F, Amin S, Noor M, Bahadur S, Gul H, Mahmood A, et al. Mortality of patients
- with severe COVID-19 in the Intensive Care Unit: An observational study from a major COVID-
- 287 19 receiving hospital. Cureus. 2020;12(10): e10906. doi: <u>10.7759/cureus.10906</u>.

288	15.	Baneriee J. C	anamar CP.	Vovageur C.	Tangpraphap	horn S. L	Lemus A. C	Coffey C, et al.

- 289 Mortality and Readmission Rates Among Patients With COVID-19 After Discharge From Acute
- 290 Care Setting With Supplemental Oxygen. JAMA Netw Open. 2021;4(4):e213990. doi:
- 291 10.1001/jamanetworkopen.2021.3990.
- 16. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors
- for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.

294 PLOS ONE. 2021;16(3): e0247461. doi: <u>10.1371/journal.pone.0247461</u>.

- 295 17. Az A, Sogut O, Akdemir T, Ergenc H, Dogan Y, Cakirca M. Impacts of demographic and
- clinical characteristics on disease severity and mortality in patients with confirmed COVID-19.

297 Int J Gen Med. 2021;14: 2989-3000. doi: <u>10.2147/IJGM.S317350</u>.

298 18. UlHaq Z, Shahzad M, Khattak MI, Fazid S, Ullah N, Shireen A, et al. Clinical

299 Characteristics, Mortality and Associated risk factors in COVID-19 patients reported in ten

300 major hospitals of Khyber Pakhtunkhwa, Pakistan. J Ayub Med Coll Abbottabad JAMC.

301 2020;32 [Suppl: 1] (4): S633-S639.


Nasir N, Habib K, Khanum I, Khan N, Muhammad ZA, Mahmood SF. Predictors of
severity and mortality of COVID-19 at a tertiary care center in a Lower-middle income country.

Authorea Preprints. 2020 Oct 1.

Adnan D, Deshmukh AA, Khan SR, Rempert T, Dhana K, Mahdavinia M, et al.. S1358
gastrointestinal symptoms predict the outcomes of COVID-19 infection. Am J Gastroenterol.
2020;115(1): S685-S686. doi: 10.14309/01.ajg.0000707480.23480.66.

- 308 21. Ramachandran P, Onukogu I, Ghanta S, Gajendran M, Perisetti A, Goyal H, et al.
- 309 Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig
- 310 Dis. 2020;38(5): 373-379.
- 311 22. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity
- and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8): 1069-1076. doi:
- 313 <u>10.1007/s42399-020-00363-4</u>.
- Ali I. Syndemics at play: Chronic kidney disease, diabetes and COVID-19 in Pakistan.
- Ann Med. 2021;53(1): 581-586. doi: <u>10.1080/07853890.2021.1910335</u>.
- 316 24. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity:
- 317 Studying the clinical and demographic risk factors for adverse outcomes. PLOS ONE.
- 318 2021;16(8): e0255999. doi: <u>10.1371/journal.pone.0255999</u>.


(A) Fever



Survival functions 1.0 Shortness of breath No 0.8 Yes No-censored Yes-censored Cum survival 0.6 0.4 0.2 0.0 20 40 60 0 80 100 Time (days) Shortness of breath Number at risk No 297 17 3 0 0 0 790 2 0 Yes 52 8 1 0 20 40 60 80 100


(C) Ischemic heart disease


(D) Nausea & Vomiting



Survival functions

(B) Shortness of breath





Figure